Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 3/2015

01.03.2015 | Original Article – Clinical Oncology

Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer

verfasst von: Marta Scorsetti, Tiziana Comito, Angelo Tozzi, Pierina Navarria, Antonella Fogliata, Elena Clerici, Pietro Mancosu, Giacomo Reggiori, Lorenza Rimassa, Guido Torzilli, Stefano Tomatis, Armando Santoro, Luca Cozzi

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the feasibility and efficacy of stereotactic body radiation therapy (SBRT) in the treatment of colorectal liver metastases.

Methods

Forty-two patients with inoperable colorectal liver metastases not amenable to radiofrequency ablation (RFA) were treated with SBRT for a total number of 52 lesions. All patients received a total dose of 75 Gy in 3 consecutive fractions. Mean size of the lesions was 3.5 cm (range 1.1–5.4). Toxicity was classified according to the Common Toxicity Criteria version 3.0.

Results

Median follow-up was 24 (range 4–47) months. The progression in field was observed in 5 lesions. Twenty-four months actuarial local control (LC) rate was 91 %. Median overall survival (OS) was 29.2 ± 3.7 months. Actuarial OS rate at 24 months was 65 %. Median progression-free survival was 12.0 ± 4.2 months; 24 months actuarial rate was 35 %. No patients experienced radiation-induced liver disease or grade ≥3 toxicity.

Conclusions

SBRT represents a feasible alternative for the treatment of colorectal liver metastases not amenable to surgery or other ablative treatments in selected patients, showing optimal LC and promising survival rate.
Literatur
Zurück zum Zitat Adam R, Wicherts DA, De Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835CrossRefPubMed Adam R, Wicherts DA, De Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835CrossRefPubMed
Zurück zum Zitat Adam R, De Gramont A, Figueras R et al (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17:1225–1239CrossRefPubMedCentralPubMed Adam R, De Gramont A, Figueras R et al (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17:1225–1239CrossRefPubMedCentralPubMed
Zurück zum Zitat Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M (2012) Review and uses of stereotactic body radiation therapy for oligometastases Oncologist 17:1100–1107 Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M (2012) Review and uses of stereotactic body radiation therapy for oligometastases Oncologist 17:1100–1107
Zurück zum Zitat Ambrosino G, Polistina F, Costantin G et al (2009) Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res 29:3381–3384PubMed Ambrosino G, Polistina F, Costantin G et al (2009) Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res 29:3381–3384PubMed
Zurück zum Zitat Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo M, Brandi G (2006) Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 32:214–228CrossRefPubMed Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo M, Brandi G (2006) Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 32:214–228CrossRefPubMed
Zurück zum Zitat Bozzetti F, Cozzaglio L, Boracchi P, Marubini E, Doci R, Bignami P, Gennari L (1993) Comparing surgical resection of limited hepatic metastases from colorectal cancer to non-operative treatment. Eur J Surg Oncol 19:162–167PubMed Bozzetti F, Cozzaglio L, Boracchi P, Marubini E, Doci R, Bignami P, Gennari L (1993) Comparing surgical resection of limited hepatic metastases from colorectal cancer to non-operative treatment. Eur J Surg Oncol 19:162–167PubMed
Zurück zum Zitat Chang D, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:4060–4069CrossRefPubMed Chang D, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:4060–4069CrossRefPubMed
Zurück zum Zitat Cirocchi R, Trastulli S, Boselli C et al (2012) Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev 6:CD006317PubMed Cirocchi R, Trastulli S, Boselli C et al (2012) Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev 6:CD006317PubMed
Zurück zum Zitat Clancy C, Burke J, Barry M, Kalady M, Coffey J (2014) A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol. doi:10.1245/s10434-014-3805-4 PubMed Clancy C, Burke J, Barry M, Kalady M, Coffey J (2014) A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol. doi:10.​1245/​s10434-014-3805-4 PubMed
Zurück zum Zitat Corbin K, Hellman S, Weichselbaum R (2013) Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 31:1384–1390CrossRefPubMed Corbin K, Hellman S, Weichselbaum R (2013) Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 31:1384–1390CrossRefPubMed
Zurück zum Zitat Dawson LA, Lawrence TS (2004) The role of radiotherapy in the treatment of liver metastases. Cancer 10:139–144CrossRef Dawson LA, Lawrence TS (2004) The role of radiotherapy in the treatment of liver metastases. Cancer 10:139–144CrossRef
Zurück zum Zitat Dawson LA, Normolle D, Balter JM et al (2002) Analysis of radiation induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821CrossRefPubMed Dawson LA, Normolle D, Balter JM et al (2002) Analysis of radiation induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821CrossRefPubMed
Zurück zum Zitat Demaria S, Formenti S (2012) Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2:153PubMedCentralPubMed Demaria S, Formenti S (2012) Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2:153PubMedCentralPubMed
Zurück zum Zitat Eisenhauer E, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer E, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
Zurück zum Zitat Eriguchi T, Takeda A, Sanuki N et al (2013) Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys 85:1006–1011CrossRefPubMed Eriguchi T, Takeda A, Sanuki N et al (2013) Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys 85:1006–1011CrossRefPubMed
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, France. http://​globocan.​iarc.​fr
Zurück zum Zitat Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318CrossRefPubMedCentralPubMed Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318CrossRefPubMedCentralPubMed
Zurück zum Zitat Gillams A, Lees W (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19:1206–1213CrossRefPubMed Gillams A, Lees W (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19:1206–1213CrossRefPubMed
Zurück zum Zitat Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493CrossRefPubMed Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493CrossRefPubMed
Zurück zum Zitat Herfarth KK, Debus J (2005) Stereotactic radiation therapy for liver metastases. Chirurg 76:564–569CrossRefPubMed Herfarth KK, Debus J (2005) Stereotactic radiation therapy for liver metastases. Chirurg 76:564–569CrossRefPubMed
Zurück zum Zitat Hoyer M, Roed H, Traberg HA et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830CrossRefPubMed Hoyer M, Roed H, Traberg HA et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830CrossRefPubMed
Zurück zum Zitat Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P (2007) Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 67:793–798CrossRefPubMed Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P (2007) Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 67:793–798CrossRefPubMed
Zurück zum Zitat Kavanagh BD, Bradley JD, Timmerman RD (2008) Stereotactic irradiation of tumors outside the central nervous system. In: Halperin EC, Perez CA, Brady LW (eds) Perez and Brady’s principles and practice of radiation oncology, 5th edn. Lippincott, Williams and Wilkins, Baltimore, pp 389–390 Kavanagh BD, Bradley JD, Timmerman RD (2008) Stereotactic irradiation of tumors outside the central nervous system. In: Halperin EC, Perez CA, Brady LW (eds) Perez and Brady’s principles and practice of radiation oncology, 5th edn. Lippincott, Williams and Wilkins, Baltimore, pp 389–390
Zurück zum Zitat Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591CrossRefPubMed Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591CrossRefPubMed
Zurück zum Zitat Leonard G, Brenner B, Kemeny N (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23:2038–2048CrossRefPubMed Leonard G, Brenner B, Kemeny N (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23:2038–2048CrossRefPubMed
Zurück zum Zitat Quan D, Gallinger S, Nhan C, On behalf of the Surgical Oncology Program at Cancer Care Ontario et al (2012) The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 151:860–870CrossRefPubMed Quan D, Gallinger S, Nhan C, On behalf of the Surgical Oncology Program at Cancer Care Ontario et al (2012) The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 151:860–870CrossRefPubMed
Zurück zum Zitat Rule W, Timmerman R, Abdulrahman R et al (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 18:1081–1087CrossRefPubMed Rule W, Timmerman R, Abdulrahman R et al (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 18:1081–1087CrossRefPubMed
Zurück zum Zitat Rusthoven KE, Kavanagh BD, Cardenes H et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572–1578CrossRefPubMed Rusthoven KE, Kavanagh BD, Cardenes H et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572–1578CrossRefPubMed
Zurück zum Zitat Saltz LB (2005) Metastatic colorectal cancer: is there one standard approach? Oncology (Williston Park) 19:1147–1154 Saltz LB (2005) Metastatic colorectal cancer: is there one standard approach? Oncology (Williston Park) 19:1147–1154
Zurück zum Zitat Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77:1241–1246CrossRefPubMed Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77:1241–1246CrossRefPubMed
Zurück zum Zitat Scorsetti M, Arcangeli S, Tozzi A et al (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastasis? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86:336–342 CrossRefPubMed Scorsetti M, Arcangeli S, Tozzi A et al (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastasis? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86:336–342 CrossRefPubMed
Zurück zum Zitat Siperstein A, Berber E, Ballem N, Parikh R (2007) Survival after radiofrequency ablation of colorectal liver metastases. 10-year experience. Ann Surg 246:559–567CrossRefPubMed Siperstein A, Berber E, Ballem N, Parikh R (2007) Survival after radiofrequency ablation of colorectal liver metastases. 10-year experience. Ann Surg 246:559–567CrossRefPubMed
Zurück zum Zitat Timmerman R, Papiez L, McGarry R et al (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955CrossRefPubMed Timmerman R, Papiez L, McGarry R et al (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955CrossRefPubMed
Zurück zum Zitat Tomlinson J, Jarnagin W, Dematteo R et al (2007) Actual 10-year survival after resection of 514 colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580CrossRefPubMed Tomlinson J, Jarnagin W, Dematteo R et al (2007) Actual 10-year survival after resection of 514 colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580CrossRefPubMed
Zurück zum Zitat van der Pool A, Mendez Romero A, Wunderink W et al (2010) Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97:377–382CrossRefPubMed van der Pool A, Mendez Romero A, Wunderink W et al (2010) Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97:377–382CrossRefPubMed
Zurück zum Zitat Yoon S, Tanabe K (1999) Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist 4:197–208PubMed Yoon S, Tanabe K (1999) Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist 4:197–208PubMed
Metadaten
Titel
Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer
verfasst von
Marta Scorsetti
Tiziana Comito
Angelo Tozzi
Pierina Navarria
Antonella Fogliata
Elena Clerici
Pietro Mancosu
Giacomo Reggiori
Lorenza Rimassa
Guido Torzilli
Stefano Tomatis
Armando Santoro
Luca Cozzi
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1833-x

Weitere Artikel der Ausgabe 3/2015

Journal of Cancer Research and Clinical Oncology 3/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.